AG
NYMX

Advisor Group’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Advisor Group’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8,645
Closed -$26.8K – 4673
2016
Q3 		$28K Sell
8,645
-633
-7% -$2.07K ﹤0.01% 2941
2016
Q2 		$31K Buy
+9,278
New +$22.8K ﹤0.01% 2773

Other funds holding NYMX

WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Advisor Group's NYMX Position: Q4 2016 in Review

Advisor Group sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2016, closing a stake of 8,645 shares — an estimated $26.8K sold.

Advisor Group first reported a position in NYMX in Q2 2016 and held it in 2 quarters. The position peaked at $31K in Q2 2016. 29 funds tracked by Wall St. Rank hold NYMX as of Q4 2016.

  • Advisor Group reported no remaining Nymox Pharmaceutical Corp position as of Q4 2016 after selling out during the quarter.
  • Advisor Group sold 8,645 Nymox Pharmaceutical Corp shares in Q4 2016, an estimated $26.8K.
  • Advisor Group first reported a position in Nymox Pharmaceutical Corp in Q2 2016 and held it in 2 quarters.
  • Advisor Group's Nymox Pharmaceutical Corp position peaked at $31K in Q2 2016.
  • 29 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2016.

Based on Advisor Group's 13F filing for Q4 2016, filed 31 Jan 2017.